On June 10, 2024 Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV: TLT) (OTCQB: TLTFF) a clinical stage pharmaceutical company that is dedicated to the research and development of light and/or radiation activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, reported that it’s lead compound, RuvidarTM, combined with transferrin to form the compound Rutherrin, has been proven effective preclinically in the destruction of Non-Small Cell Lung Cancer ("NSCLC") (Press release, Theralase, JUN 10, 2024, View Source [SID1234644217]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Theralase recently completed experiments in NSCLC, using a Lewis Lung Cancer ("LLC1") orthotopic model. In this model, mouse lungs are subjected to lung cancer cells, which induces these mice to develop very aggressive, fast growing and metastatic lung tumours.

As shown in Figure 1, lung tumours retained Rutherrin longer than normal lung tissues (p> 0.01), leading to a substantially improved selectivity of Rutherrin to target lung cancer.